drugset / Trial / NCT03034460
Efficacy and Safety of CD5024 1% in Acne Vulgaris
RandomizedParallel-groupSingle-blindOther
Summary
Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.
Timeline
- Start
- 2016-04-25
- Primary completion
- 2016-11-02
- Completion
- 2016-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD0271/CD1579 | Unknown | 0.5 ml | Topical |
| Subject | Ivermectin | Small molecule | 0.5 ml | Topical |
| Subject | Ivermectin | Small molecule | 1 % | Topical |